Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders

Autism spectrum disorders (ASDs) include three main conditions: autistic disorder (AD), pervasive developmental disorder, not otherwise specified (PDD-NOS), and Asperger syndrome. It has been shown that many genes associated with ASDs are involved in the neuroligin–neurexin interaction at the glutamate synapse: NLGN3, NLGN4, NRXN1, CNTNAP2, and SHANK3. We screened this last gene in two cohorts of ASD patients (133 patients from US and 88 from Italy). We found 5/221 (2.3%) cases with pathogenic alterations: a 106 kb deletion encompassing the SHANK3 gene, two frameshift mutations leading to premature stop codons, a missense mutation (p.Pro141Ala), and a splicing mutation (c.1820-4 G>A). Additionally, in 17 patients (7.7%) we detected a c.1304+48C>T transition affecting a methylated cytosine in a CpG island. This variant is reported as SNP rs76224556 and was found in both US and Italian controls, but it results significantly more frequent in our cases than in the control cohorts. The variant is also significantly more common among PDD-NOS cases than in AD cases. We also screened this gene in an independent replication cohort of 104 US patients with ASDs, in which we found a missense mutation (p.Ala1468Ser) in 1 patient (0.9%), and in 8 patients (7.7%) we detected the c.1304+48C>T transition. While SHANK3 variants are present in any ASD subtype, the SNP rs76224556 appears to be significantly associated with PDD-NOS cases. This represents the first evidence of a genotype–phenotype correlation in ASDs and highlights the importance of a detailed clinical-neuropsychiatric evaluation for the effective genetic screening of ASD patients.

[1]  Yiping Shen,et al.  High Proportion of 22q13 Deletions and SHANK3 Mutations in Chinese Patients with Intellectual Disability , 2012, PloS one.

[2]  D. Geschwind,et al.  Heterogeneous dysregulation of microRNAs across the autism spectrum , 2008, neurogenetics.

[3]  T. Boeckers,et al.  C‐terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/Shank2 and ProSAP2/Shank3 , 2005, Journal of neurochemistry.

[4]  R. Huganir,et al.  Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. , 2011, American journal of human genetics.

[5]  Christian R Marshall,et al.  Contribution of SHANK3 mutations to autism spectrum disorder. , 2007, American journal of human genetics.

[6]  Ken Garber,et al.  Autism's Cause May Reside in Abnormalities at the Synapse , 2007, Science.

[7]  Thomas Bourgeron,et al.  Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders , 2007, Nature Genetics.

[8]  M. Cuccaro,et al.  Autism and maternally derived aberrations of chromosome 15q. , 1998, American journal of medical genetics.

[9]  C. Sala,et al.  DNA methylation regulates tissue‐specific expression of Shank3 , 2007, Journal of neurochemistry.

[10]  T. Bourgeron,et al.  SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism , 2011, Molecular Psychiatry.

[11]  Dai Zhang,et al.  Association study of SHANK3 gene polymorphisms with autism in Chinese Han population , 2009, BMC Medical Genetics.

[12]  T. Südhof,et al.  Dissection of Synapse Induction by Neuroligins , 2005, Journal of Biological Chemistry.

[13]  Yiping Shen,et al.  Disruption of neurexin 1 associated with autism spectrum disorder. , 2008, American journal of human genetics.

[14]  M. Chiappalone,et al.  Importance of Shank3 Protein in Regulating Metabotropic Glutamate Receptor 5 (mGluR5) Expression and Signaling at Synapses , 2011, The Journal of Biological Chemistry.

[15]  J. Baio.  Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. , 2012, Morbidity and mortality weekly report. Surveillance summaries.

[16]  R. Borgatti,et al.  Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. , 2001, American journal of human genetics.

[17]  Marie-Pierre Dubé,et al.  De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia , 2010, Proceedings of the National Academy of Sciences.

[18]  S. Scherer,et al.  Molecular Cytogenetics of Autism , 2004 .

[19]  G. B. Schaefer,et al.  Clinical genetics evaluation in identifying the etiology of autism spectrum disorders , 2008, Genetics in Medicine.

[20]  Mark J. Harris,et al.  Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication , 2010, Molecular autism.

[21]  Peter J. Scambler,et al.  22q11.2 deletion syndrome. , 2015, Nature reviews. Disease primers.

[22]  A. Beaudet,et al.  Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. , 2011, Human molecular genetics.

[23]  Jens Frahm,et al.  Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism , 2008, Proceedings of the National Academy of Sciences.

[24]  D. Linden,et al.  RETRACTED: Enhanced Polyubiquitination of Shank3 and NMDA Receptor in a Mouse Model of Autism , 2011, Cell.

[25]  Inês Sousa,et al.  Copy number variation and association analysis of SHANK3 as a candidate gene for autism in the IMGSAC collection , 2009, European Journal of Human Genetics.

[26]  Laurent Mottron,et al.  Novel de novo SHANK3 mutation in autistic patients , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[27]  D. Pinto,et al.  Structural variation of chromosomes in autism spectrum disorder. , 2008, American journal of human genetics.

[28]  A. Bailey,et al.  Autism as a strongly genetic disorder: evidence from a British twin study , 1995, Psychological Medicine.

[29]  Katarzyna Chawarska,et al.  Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. , 2008, American journal of human genetics.

[30]  N. Okamoto,et al.  Novel variants of the SHANK3 gene in Japanese autistic patients with severe delayed speech development , 2011, Psychiatric genetics.

[31]  A G Dean,et al.  Epi Info: a general-purpose microcomputer program for public health information systems. , 1991, American journal of preventive medicine.

[32]  Allen D. Delaney,et al.  Conserved Role of Intragenic DNA Methylation in Regulating Alternative Promoters , 2010, Nature.

[33]  Thomas Bourgeron,et al.  Mapping autism risk loci using genetic linkage and chromosomal rearrangements , 2007, Nature Genetics.

[34]  D. Pinto,et al.  Contribution of SHANK 3 Mutations to Autism Spectrum Disorder , 2007 .

[35]  G. Feng,et al.  Shank3 mutant mice display autistic-like behaviours and striatal dysfunction , 2011, Nature.

[36]  H. McDermid,et al.  Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms , 2003, Journal of medical genetics.

[37]  Alexander R. Griffing,et al.  Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. , 2010, American journal of human genetics.

[38]  Kenny Q. Ye,et al.  Strong Association of De Novo Copy Number Mutations with Autism , 2007, Science.

[39]  K. McBride,et al.  Genetic testing in autism: how much is enough? , 2007, Genetics in Medicine.

[40]  Charles E. Schwartz,et al.  High frequency of neurexin 1β signal peptide structural variants in patients with autism , 2006, Neuroscience Letters.

[41]  Jacqueline Blundell,et al.  A Neuroligin-3 Mutation Implicated in Autism Increases Inhibitory Synaptic Transmission in Mice , 2007, Science.

[42]  Thomas Bourgeron,et al.  Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism , 2003, Nature Genetics.

[43]  J. Sebat,et al.  Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. , 2008, American journal of human genetics.

[44]  J. Miles.  Autism spectrum disorders—A genetics review , 2011, Genetics in Medicine.

[45]  J. Buxbaum,et al.  Molecular Autism: accelerating and integrating research into neurodevelopmental conditions , 2010, Molecular autism.

[46]  Tanya M. Teslovich,et al.  A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. , 2008, American journal of human genetics.

[47]  E. Fombonne,et al.  Pervasive developmental disorders in preschool children. , 2001, JAMA.

[48]  R Redon,et al.  Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders , 2006, Journal of Medical Genetics.

[49]  S Arndt,et al.  Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. , 1997, The American journal of psychiatry.

[50]  Edwin H Cook,et al.  Autism as a paradigmatic complex genetic disorder. , 2004, Annual review of genomics and human genetics.